Replimune Group (NASDAQ:REPL) CFO Emily Luisa Hill Sells 14,709 Shares of Stock

Replimune Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CFO Emily Hill sold 14,709 shares at an average price of $21.60, totaling about $317,714; the sale covered tax withholding on vested equity awards. She retained 201,143 shares after the transaction.
  • Replimune reported a quarterly loss of $0.54 per share, beating analysts’ estimate of a $0.78 loss by $0.24.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $18.17; the shares traded at $19.81 in the article’s cited session.
  • Five stocks to consider instead of Replimune Group.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CFO Emily Hill sold 14,709 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $21.60, for a total value of $317,714.40. Following the completion of the sale, the chief financial officer directly owned 201,143 shares of the company's stock, valued at $4,344,688.80. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Up 0.6%

NASDAQ:REPL traded up $0.12 during trading hours on Wednesday, hitting $19.81. 2,130,078 shares of the company traded hands, compared to its average volume of 3,489,130. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The company has a market cap of $1.88 billion, a PE ratio of -7.10 and a beta of 0.93. The firm's 50-day simple moving average is $15.10 and its 200-day simple moving average is $10.23. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $23.54.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.24. Equities analysts predict that Replimune Group, Inc. will post -2.38 earnings per share for the current year.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently added to or reduced their stakes in REPL. BlackRock Inc. purchased a new stake in Replimune Group during the second quarter worth about $99,171,000. Montanova Capital LLC raised its position in Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock worth $48,595,000 after acquiring an additional 168,000 shares during the period. Marshall Wace LLP purchased a new position in Replimune Group in the third quarter valued at about $50,516,000. Opaleye Management Inc. purchased a new position in Replimune Group in the second quarter valued at about $15,332,000. Finally, Dimensional Fund Advisors LP boosted its stake in Replimune Group by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company's stock valued at $8,719,000 after acquiring an additional 20,742 shares during the last quarter. Institutional investors own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on REPL. Wedbush raised shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research report on Friday, August 7th. Leerink Partners boosted their target price on Replimune Group from $19.00 to $31.00 and gave the stock an "outperform" rating in a research note on Thursday, October 29th. Cantor Fitzgerald restated an "overweight" rating on shares of Replimune Group in a research note on Monday, October 5th. JPMorgan Chase & Co. upped their target price on Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, August 26th. Finally, Wolfe Research raised Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $18.17.

Check Out Our Latest Research Report on REPL

Replimune Group Company Profile

(Get Free Report)

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company's investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.

Further Reading

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Replimune Group Right Now?

Before you consider Replimune Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.

While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines